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Abstract: GPR21 is a constitutively active, orphan, G-protein-coupled receptor, with in vivo studies 
suggesting its involvement in the modulation of insulin sensitivity. However, its precise contribu-
tion is not fully understood. As the liver is both a major target of insulin signalling and critically 
involved in glucose metabolism, the aim of this study was to examine the role of GPR21 in the 
regulation of glucose uptake and production in human hepatocytes. In particular, HepG2 cells, 
which express GPR21, were adopted as cellular models. Compared with untreated cells, a signifi-
cant increase in glucose uptake was measured in cells treated with siRNA to downregulate GPR21 
expression or with the GPR21-inverse agonist, GRA2. Consistently, a significantly higher membrane 
translocation of GLUT-2 was measured under these conditions. These effects were accompanied by 
an increased ratio of phAKT(Ser473)/tot-AKT and phGSK-3β(Ser9)/tot-GSK-3β, thus indicating a marked 
activation of the insulin signalling pathway. Moreover, a significant reduction in ERK activation 
was observed with GPR21 inhibition. Collectively, these results indicate that GPR21 mediates the 
negative effects on glucose uptake by the liver cells. In addition, they suggest that the pharmaco-
logical inhibition of GPR21 could be a novel strategy to improve glucose homeostasis and counter-
act hepatic insulin resistance. 
Keywords: GPR21; GPCRs; hepatocytes; hepatic insulin resistance 
 
1. Introduction 
Type 2 diabetes (T2D) mellitus is a chronic disease that is reaching epidemic propor-
tions, and despite several therapeutic options being available, almost half of patients do 
not achieve their treatment goals [1]. Insulin resistance plays a crucial role in its patho-
genesis and, interestingly, represents the best predictor of a future diagnosis of this pa-
thology [2]. Generally, T2D is preceded by impaired glucose tolerance, characterised by 
abnormally increased postprandial blood glucose levels due to impaired insulin sensitiv-
ity. Currently, it has been estimated that 347 million people have an impaired glucose 
tolerance [3], which is itself associated with increased cardiovascular mortality [4]. On this 
basis, advancing knowledge of the molecular mechanism underlying insulin sensitivity 
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impairment is necessary to identify novel targets for potential pharmacological strategies 
to counteract its establishment and progression. 
G-Protein Coupled Receptors (GPCRs) are a superfamily of transmembrane recep-
tors that perform a wide range of biological functions within the human body [5–7]. They 
represent a rich source of drug targets: approximately 30% of marketed drugs act through 
these receptors [8]. However, orphan receptors still comprise ~25% of the targetable GPCR 
space and are attracting particular interest in the drug discovery field as they may repre-
sent novel therapeutic targets for a range of conditions [9]. 
The Rhodopsin subfamily is the largest subset grouping of GPCRs with diverse lig-
ands including neurotransmitters, hormones, and lipids.  GPR21 is a broadly expressed, 
orphan, rhodopsin-like receptor that shows constitutive activity through Gαq type G pro-
teins, in particular Gα q and Gα 15/16 [10,11]. Interestingly, this receptor has been shown 
to be involved in the pathogenesis of insulin resistance, thus representing a potential new 
target for the treatment of Type 2 diabetes [11,12]. 
In particular, in vivo studies on GPR21 knockout (KO) mice demonstrated that the 
deletion of this receptor improves glucose tolerance and systemic insulin sensitivity in 
animals fed with a high-fat diet [13,14]. The mechanism by which GPR21 exerts its meta-
bolic phenotype is difficult to pinpoint, with Osborn et al. suggesting that GPR21 may be 
a novel control point coordinating macrophage pro-inflammatory activity in the context 
of obesity-induced insulin resistance, thus hypothesising an indirect role for this receptor 
in the induction of insulin resistance. Subsequently, we showed that GPR21 overexpres-
sion in HEK293T cells was associated with impaired insulin signalling, thus indicating a 
direct involvement in the establishment of insulin resistance [11]. In addition, we recently 
identified the acetamide GRA2, (2-(1-naphthyloxy)-N-(2-phenoxyphenyl)acetamide (Fig-
ure 1), which acts as an inverse agonist for this receptor and can counteract the influence 
of GPR21 on the insulin signalling pathway [11]. However, despite its intriguing potential, 
the effect of GPR21 in target cells for the action of insulin has not been investigated yet. 
 
Figure 1. Structure of GRA2, (2-(1-naphthyloxy)-N-(2-phenoxyphenyl)acetamide. 
The aim of this study was to investigate the ability of this receptor to affect the insulin 
sensitivity of hepatocytes. As liver tissue is crucial for the regulation of glucose homeo-
stasis, the development of insulin resistance in hepatocytes is expected to have important 
and serious systemic consequences [15]. To this purpose, the specific aims of this study 
were to investigate the effect of GPR21 in hepatocytes demonstrating its presence and ac-
tivity and analysing its effect on glucose uptake/production and insulin signalling by (1) 
siRNA down-regulation or (2) its pharmacological inhibition by using the inverse agonist 
GRA2. 
2. Results 
2.1. Expression and Activity of GPR21 in HepG2 Cells 
To evaluate whether HepG2 cells were suitable cellular models to study the role of 
GPR21 in hepatocytes, the expression of this receptor was first assessed using a Western 
blot analysis. As shown in Figure 2A, GPR21 was detected in HepG2 cells. As GPR21 is a 
constitutively active receptor [10], the effects of its inhibition were quantified. In particu-
lar, two strategies were adopted: a specific siRNA against GPR21 to decrease GPR21 ex-
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pression (Figures 2B,C) and a GPR21-inverse agonist, GRA2 [11], to inhibit receptor activ-
ity. As shown in Figures 2B,C, GPR21 expression at the gene and protein levels was sig-
nificantly reduced by using specific siRNA against GPR21. By contrast, cell exposure to 
GRA2 (3–30 µM, 24 h), did not affect GPR21 expression (Figure 2D). Moreover, GRA2 (1–
30 µM, 24 h) did not affect cell viability as evaluated by the MTT assay (Figure 2E). 
 
Figure 2. GPR21 receptor expression in HepG2 cells. (A). Representative Western blot analysis for 
the expression of GPR21 in HepG2 cells (MW: 37 kDa, C+: HT1080 whole cells lysate). Tubulin ex-
pression was assessed to confirm homogeneity of loading. (B). qPCR analysis for GPR21 mRNA in 
HepG2 cells transfected with non-silencing siRNA (SC) or with siRNA for GPR21 (siRNA). Data are 
expressed as mean ± SEM of three independent experiments run in triplicate. (C). Western blot anal-
ysis of GPR21 protein levels in HepG2 cells transfected with non-silencing siRNA (SC) or with 
siRNA for GPR21 (siRNA) (left panel). Equal loading was evaluated by re-probing the membrane 
with anti-tubulin. The relative densitometric analysis is reported in the right panel. (D). Western 
blot analysis of the GPR21 receptor exposed to either vehicle alone or GRA2 (3–30 µM, 24 h). Equal 
loading was evaluated by re-probing the membrane with anti-tubulin. (E). MTT assay on HepG2 
cells exposed to either vehicle alone or increasing concentrations of GRA2 (1–30 µM) for 24 h. Cell 
growth was expressed as a percentage of the control cultures (100%). Data are expressed as mean ± 
SEM of three independent experiments run in triplicate. * p < 0.05 vs. scramble control (SC). 
However, as shown in Figure 3A, the use of a specific siRNA against GPR21 signifi-
cantly (p < 0.05) decreased IP1 levels, which appeared to be approximately 40% lower 
compared to the Scramble Control (SC)-treated samples. In addition, GRA2 decreased IP1 
production levels in a concentration-dependent manner with a significant (p < 0.05) inhi-
bition at concentrations above 10 µM (IC50 of 1.6 × 10−6 M, Figure 3B). These results sug-
gest that GPR21 is a constitutively active receptor in HepG2 cells and that GRA2 was able 
to act as an inverse agonist in our experimental model. Therefore, as indicated by these 
results, HepG2 cells represent a suitable in vitro model to study the role of this receptor 
in hepatocytes. 




Figure 3. Effect of GPR21 gene silencing and GRA2 treatment on IP1 production. GPR21 constitutive 
activation was quantified by measuring the intracellular IP1 level in HepG2 cells transfected with 
non-silencing siRNA (SC, Scramble) or silenced with siRNA against GPR21 for 72 h (panel (A)) as 
well as in HepG2 cells treated with increasing concentrations of the inverse agonist (3–30 µM, for 1 
h, panel (B)). Data are expressed as mean ± SEM of four independent experiments run in duplicate. 
Values are expressed in % vs. control or scramble. * p < 0.05 vs. control or scramble. 
2.2. Effect of GPR21 Gene Silencing and GRA2 Treatment on Glucose Uptake and Glucose 
Production in HepG2 Cells 
The liver plays a crucial role in glucose homeostasis, with glucose uptake by hepato-
cytes considered an essential element driving hepatic insulin resistance. To assess whether 
GPR21 contributes to the regulation of cellular glucose homeostasis, the effects of GPR21 
gene silencing and of GRA2 on glucose uptake were measured. As shown in Figure 4A, 
GPR21 gene silencing significantly increased glucose uptake (p < 0.05) in comparison to 
HepG2 cells transfected with scramble control (SC) sequences. Consistently, in compari-
son to control cells, a concentration-dependent increase in glucose uptake was also meas-
ured in cells treated with GRA2 (Figure 4B). Additionally, we evaluated whether GPR21 
affects glucose production in HepG2 cells. The inhibition of GPR21 by gene silencing (Fig-
ure 4C) or by GRA2 treatment (Figure 4D) did not affect cellular glucose production, sug-
gesting that GPR21 could impair glucose homeostasis primarily through its effect on glu-
cose uptake. 
 
Figure 4. Effect of GPR21 gene silencing and GRA2 treatment on hepatic glucose homeostasis. Glu-
cose uptake was assessed using a 2-NBDG fluorescent probe; HepG2 cells were transfected for 72 h 
with non-silencing siRNA (scramble, SC) or with specific siRNA against GPR21 (siRNA, panel (A)) 
or exposed to increasing concentrations of inverse agonist GRA (3–30 µM, 24 h, panel (B)). Data are 
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expressed as mean ± SEM (n = 4) in % vs. control or scramble. * p < 0.05 vs. scramble control (SC); ** 
p < 0.01 vs. control. D,E. Glucose production was evaluated on HepG2 cells transfected with non-
silencing siRNA (SC) or with GPR21 siRNA (C) or exposed to increasing concentrations of inverse 
agonist GRA2 (3–30 µM, 24 h, panel (D)). Values are expressed in % vs. control or scramble. Data 
are expressed as mean ± SEM (n = 3) in % vs. control or scramble. 
2.3. Effect of GPR21 Gene Silencing and GRA2 Treatment on GLUT-2 Expression 
Since our results indicated an increased glucose uptake after the inhibition of GPR21, 
we investigated whether GPR21 can affect the membrane expression of the prominent 
glucose transporter mainly present in the liver, GLUT-2 [16]. We evaluated GLUT-2 ex-
pression in HepG2 cells by performing flow cytometry analysis (Figure 5 and supple-
mental Figure S1). Our data showed that the selected silencing of GPR21 by specific siRNA 
(Figures 5A and S1A) as well as the inhibition of GPR21 activity by GRA2 treatment (30 
µM, Figures 5B and Figure S1B) resulted in the increased translocation of GLUT-2 to the 
HepG2 cell membrane, thus explaining and justifying the increase in glucose uptake. 
 
Figure 5. GPR21 inhibition improves GLUT-2 translocation to the plasma membrane. Flow cytom-
etry analysis of GLUT-2 expression at the cell membrane of HepG2 cells transfected with non-si-
lencing siRNA (SC) or with specific Scheme 21. (siRNA, (A)) or exposed to GRA2 (30 µM, 24 h, panel 
(B)). Data are expressed as the mean of fluorescence FL-1 ± SEM; n = 4. * p < 0.05 vs. control; *** p < 
0.001 vs. scramble control (SC). 
2.4. Effect of GPR21 Inhibition on Insulin Signalling in HepG2 Cells 
As AKT- GSK-3β signalling is a crucial regulator of GLUT-2 expression [17,18], which 
is affected by GPR21 inhibition, we evaluated the phosphorylation status of these target 
proteins. In particular, we evaluated the ratio of Ser473Akt/tot Akt and Ser9GSK-3β/tot 
GSK-3β. As shown in Figure 6, in HepG2 cells, gene silencing or the pharmacological in-
hibition of GPR21 induced an improvement of the insulin signalling pathway. In particu-
lar, our results demonstrated that the selected silencing of GPR21 receptors (by siRNA) 
resulted in a significant increase in the phosphorylation of Ser473Akt, which is essential for 
the full activation of this enzyme. Consistently, this effect was associated with a significant 
increase in the phosphorylation of Ser9 GSK-3β compared to SC (Figures 6A,C). GSK-3β 
is a constitutively active enzyme that could be inhibited by the phosphorylation of Ser9. 
Thus, an increase in the ratio of Ser9 GSK-3β/tot GSK-3β indicates an inhibition of its ac-
tivity that results in an increased expression of GLUT-2. As shown in panel B, the same 
results were achieved in cells treated with GRA2. The effect was dose-dependent and be-
came significant at the higher dose (p < 0.05, Figures 6B,D). 




Figure 6. Effect of GPR21 inhibition on insulin signalling in HepG2 cells. Western blot analysis of 
phosphorylation levels of Ser473Akt and Ser9GSK-3β in HepG2 cells transfected for 72 h with non-
silencing siRNA (scramble control, SC) or with specific siRNA against GPR21 (siRNA, panel (A,C)) 
as well as in HepG2 cells exposed to increasing concentrations of inverse agonist GRA2 (3–30 µM, 
24 h, panel (B,D)). Equal loading was evaluated by a re-probing membrane with total Akt or GSK-
3β. Densitometric analysis of the bands is expressed as relative optical density (O.D.) and was nor-
malised using the related control band. Data are expressed as mean ± SEM; n = 4. * p < 0.05 vs. 
scramble control (SC) or control. 
2.5. Effect of GPR21 Gene Silencing and GRA2 Treatment on ERK Activation 
As there is known cross talk between the insulin-AKT and MAPK/ERK signalling 
pathways [19] and that the insulin signalling could be negatively affected by ERK activa-
tion [20–22], we evaluated the effect of GPR21 inhibition on ERK phosphorylation. As 
shown in Figure 7, both gene silencing (Figure 7A) and the pharmacological inhibition of 
GPR21 (Figure 7B) induced a significant reduction in ERK phosphorylation, thus leading 
to a decrease in its activity. In particular, our results demonstrated that the inverse agonist 
GRA2 exerted a dose-dependent effect that became significant at the higher dose (p < 0.05). 




Figure 7. Effect of GPR21 gene silencing and GRA2 treatment on ERK activation. Western blot anal-
ysis of the phosphorylation levels of the MAPK ERK1/2 in HepG2 cells transfected for 72 h with 
non-silencing siRNA (scramble control, SC) or with specific Scheme 21. (siRNA, panel (A)) as well 
as in HepG2 cells exposed to increasing concentrations of the inverse agonist GRA2 (3–30 µM, 24 h, 
panel (B)). Equal loading was evaluated by a re-probing membrane with total ERK1/2. Densitomet-
ric analysis of the bands is expressed as relative optical density (O.D.) and normalised using the 
related control band. Data are expressed as mean ± SEM; n = 3. * p < 0.05 vs. scramble control (SC) 
or control. 
3. Discussion 
Insulin resistance is defined as the increased requirement for insulin to maintain glu-
cose homeostasis and it is a consistent finding in patients affected by T2D [15]. T2D pa-
tients have elevated blood glucose levels due to an impaired pancreatic insulin produc-
tion/secretion and a reduction in glucose uptake due to a decreased insulin activity in the 
peripheral organs, such as the liver and muscle. As the liver plays a central role in glucose 
metabolism by maintaining a balance between its uptake and storage, hepatic insulin re-
sistance is thought to be largely responsible for the development of fasting hyperglycae-
mia [23]. While liver function is regulated by GPCRs, knowledge of how GPCRs regulate 
liver metabolism is limited [24]. A better understanding of the metabolic role of GPCRs in 
hepatocytes could lead to the development of novel drugs for the treatment of pathologi-
cal conditions, including T2D. 
This study focused on the orphan receptor, GPR21, which previous results have sug-
gested is involved in the pathogenesis of insulin resistance [11,13,14], showing for the first 
time the presence of this receptor in HepG2 cells, and confirming its constitutive activity. 
By inhibiting GPR21 with selected siRNA, we demonstrated that this receptor nega-
tively affects glucose uptake and insulin signalling in hepatocytes. Interestingly, we also 
showed the possibility of counteracting GPR21 activity by using the inverse agonist 
GRA2. 
Consistently, we observed a statistically significant increased expression of GLUT-2 
on the membrane of the cells downregulated for GPR21 or treated with GRA2. GLUT-2 is 
the major glucose transporter expressed in hepatocytes [25]. The role of this high-capacity 
and low affinity glucose transporter is to take up glucose absorbed during feeding, pre-
venting marked postprandial hyperglycaemia and to release it in the blood during fasting 
[16]. 
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The expression of GLUT-2 is not correlated to hepatic glucose output. In vivo studies 
showed that the deletion of GLUT-2 suppressed glucose uptake but, unexpectedly, did 
not impair glucose output, thus suggesting that glucose trafficking across the membrane 
is differently mediated with respect to uptake and output and supporting the existence of 
a second pathway for glucose output [26–28]. These results are consistent with our data. 
We did not observe an increased glucose output in cells with the increased expression of 
GLUT-2. 
However, the action of GLUT-2 is not limited to glucose transport. Several studies 
have indicated that it could be important for the control of glucose-sensitive gene expres-
sion in the liver. Hughes et al. suggested a role for GLUT-2 as a component of the glucose-
sensing apparatus that regulates insulin release from the cells in response to changes in 
external glucose concentration [29]. More recently, Seyer et al. showed that hepatic GLUT-
2 inactivation induces a long-term, progressive development of glucose intolerance, thus 
suggesting the existence of a liver/β cell axis that depends on normal liver glucose metab-
olism [30]. Interestingly, this suggests that GLUT-2 expressed by hepatocytes could have 
an important impact on β cell function, thus allowing us to speculate that GPR21 inhibi-
tion could also have an indirect but positive effect on beta cells. 
In addition, GLUT-2 is markedly expressed in β-cells where it acts as a first messen-
ger to trigger glucose signalling [18,31]. Interestingly, it has been observed that islet cells 
from human donors with Type 2 diabetes showed a significant (80–90%) reduction in 
GLUT-2 expression and lacked the glucose-stimulated insulin secretion (GSIS) response, 
a marker of beta cell dysfunction in Type 2 diabetes [32]. Consistently, a decreased GLUT2 
gene expression was observed in the pancreatic cells of experimental models of diabetes 
and an impaired insulin secretion and synthesis was observed in KO mice for GLUT-2, 
but, interestingly, these effects were restored when the GLUT-2 was expressed again [33]. 
Our study is the first, to our knowledge, that has found a correlation between GPR21 ac-
tivity and GLUT-2 expression, but on this basis, we can postulate that the effects of GPR21 
inhibition deserve further investigation, in particular in the beta cells, where an increase 
in GLUT-2 could have an important impact. As several data have suggested that the AKT 
axis is crucial for the expression of GLUT-2 [18,34] and, in particular, that GSK3β is a neg-
ative modulator of its expression [17], we investigated the phosphorylation status of these 
two important protein targets of insulin signalling. Notably, we demonstrated that cells 
treated with GRA2 or siRNA for GPR21 showed an improvement of the insulin signalling 
pathways, as was evident by the observed increase in the Ser473Akt/tot Akt ratio. AKT 
phosphorylation of Ser473 is required to achieve full activation of this protein [35]. Strong 
evidence indicates that the Akt signalling pathway is key to mediating the effects of insu-
lin on the anabolic metabolism in all organisms [36]. Studies on knockout animals for AKT 
showed that the absence of this enzyme in the liver induced severe insulin resistance, glu-
cose intolerance, and a reduction in hepatic lipid synthesis, thus supporting the im-
portance of its activation to improve insulin sensitivity [37,38]. One of the main targets of 
the action of AKT is GSK-3β, a constitutively active serine/threonine protein kinase en-
zyme that controls numerous cellular processes including glycogen metabolism [39]. 
GSK-3β is a peculiar enzyme that is inhibited, rather than activated, in response to insulin 
stimulation through the phosphorylation of Ser9 [40]. Consistent with the literature data, 
our results showed that GSK-3β inhibition is associated with an increase in GLUT-2 ex-
pression. In addition, since GSK-3β inhibits glycogen synthase by phosphorylation [40], 
the suppression of GSK-3β by AKT also leads to an increase in glycogen synthesis activity, 
thus allowing us to speculate that the genetic or pharmacological inhibition of GPR21 is 
associated with an increase in the synthesis of glycogen. However, this effect did not result 
in a reduction in glucose production. In fact, we did not observe significant differences in 
this parameter in the cells treated with selected GPR21 siRNA or GPR21 inverse agonist 
in comparison with the relative controls, thus suggesting that GPR21 seems not to affect 
gluconeogenesis. 
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In addition, our data showed that GPR21 inhibition decreased ERK phosphorylation. 
ERK belongs to the mitogen-activated protein kinase family and its activity is increased 
in several tissues of diabetic mice [41–43] and in primary cells from Type 2 diabetic pa-
tients [44]. Interestingly, it is recognised that the activation of this MAPKs negatively af-
fects insulin signalling [20,22,45,46]. Consistently, the literature data has shown that the 
inhibition of the ERK pathway lowered the non-fasting blood glucose level, increased glu-
cose tolerance, and improved insulin sensitivity in db/db mice and high-fat diet-fed KKAy 
mice [21,47]. On the other hand, it has been shown that mice deficient in the signalling 
adapter p62, an ERK inhibitor, had a high basal level of ERK activity and developed ma-
ture-onset obesity and insulin resistance [43,48]. On this basis we can speculate that the 
GPR21 deleterious effect could be, at least in part, mediated by ERK. 
Overall, our results on GPR21 are supported by previous studies which have demon-
strated that the selective stimulation of a Gq-linked GPCR expressed in hepatocytes leads 
to an impaired glucose tolerance [49]. Consistently, we showed that the inhibition of 
GPR21 activity significantly improved elements of the insulin signalling pathway, with 
an inhibition of GSK-3β and increased glucose cellular uptake. Our results are particularly 
relevant as they were achieved in a basal condition, thus confirming that being constitu-
tively activated, GPR21 negatively affects insulin signalling. We can hypothesise that in 
several conditions, the activity of this receptor could increase over the controls, thus con-
tributing to insulin signalling impairment in pathological conditions such as T2D. To this 
purpose, a recent paper by Romero-Nava et al. showed a change in the genetic expression 
of GPR21 in different in vivo experimental models of metabolic syndrome, thus suggest-
ing its involvement in the pathogenesis of this condition and the hypothesis of a role for 
this receptor as a new therapeutic target [50]. 
This study has some limitations. First, as a fully in vitro study, this investigation was 
based on an experimental model of cell culture. Undoubtedly, primary cells are superior 
to permanent cell lines. However, the availability of human primary hepatocytes is very 
limited. We selected HepG2, which are cells that are frequently used to investigate hepatic 
signalling, because, despite their tumorigenic origin, they have been shown to be suitable 
to study insulin signalling [51]. Second, in our study, the effects observed with GPR21 
gene downregulation were interestingly also evident after GRA2 treatment. However, the 
doses of the inverse agonist used in this study were quite high, in the µM range, thus 
suggesting that structure–activity relationship studies are necessary to optimise GRA2, 
which is the only GPR21 inverse agonist currently available, and achieve analogues with 
a higher potency. 
Finally, we note that Wang et al. [52], by using a different methodology to achieve 
GPR21 KO mice, did not confirm the results previously achieved by Osborn and Gardner 
[13,14]. However, the experimental conditions were different, so it is not possible to arrive 
at a conclusive result without a direct comparison. In this context, our data are independ-
ent of, but consistent with, the results achieved by Osborn and Gardner and add useful 
information to better understand the role of this orphan receptor. Here, we demonstrated 
that GPR21 has a direct role on hepatic insulin sensitivity impairment, supporting previ-
ous results achieved in HEK293 cells [11]. 
In conclusion, we have shown that GPR21 negatively affects insulin sensitivity in 
hepatocytes, suggesting that its inhibition might represent a novel and promising phar-
macological strategy to counteract the development of insulin resistance. 
4. Materials and Methods 
4.1. Cell Cultures 
HepG2 cells (ATCC-HB-8065 from ATCC, USA) were cultured in Dulbecco’s modi-
fied Eagle’s medium-low glucose (DMEM, 1000 mg/L, Aurogene Srl, Rome, Italy) supple-
mented with L-glutamine (2 mM, Aurogene Srl, Rome, Italy), penicillin-streptomycin (100 
µg/mL, Aurogene Srl, Rome, Italy) and foetal bovine serum (FBS, 10% v/v, Aurogene Srl, 
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Rome, Italy), at 37 °C in a humidified 5% CO2 atmosphere incubator. HepG2 cells were 
seeded in normoxic conditions to obtain the desired sub-confluence level (65–70%) and to 
perform the experimental analyses. 
4.2. Cell Viability Evaluation 
Cells were plated (4 × 103 cells/well) in 24-well culture plates and exposed to either 
the vehicle alone (DMSO, control) or GRA2. Cell viability was quantified in sub-confluent 
cultures by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
Sigma, Sigma-Aldrich, St Louis, MO, USA) colorimetric assay. The results were confirmed 
by determining cell density, as previously described [53,54]. 
4.3. Quantification of the Inositol 1-Phosphate (IP1) Level 
Cellular IP1 levels were quantified by using an IP1 homogeneous time resolved flu-
orescence (HTRF) assay (Cisbio, PerkinElmer, Waltham MA, USA), as previously de-
scribed [55,56]. Briefly, sub-confluent cell cultures were collected and re-suspended in the 
appropriate volume of the assay stimulation buffer. Cell suspensions were added to dif-
ferent concentrations of the compound to be tested and incubated at 37 °C for 1 h. Then, 
an IP1 lysis buffer containing IP-one-d2 conjugate was added to the appropriate wells, 
followed by the anti-IP-one cryptate Tb conjugate. Samples were incubated for 1 h at room 
temperature. The plate was read on a VICTOR X4 (PerkinElmer, Waltham, MA, USA) 
plate reader with emission at 615 nm and 665 nm. The fluorescence resonance energy 
transfer (FRET) ratio (665 nm/615 nm) was converted to IP1 concentrations by interpolat-
ing values from an IP1 standard curve. 
4.4. siRNA-Mediated GPR21 Knockdown 
RNA interference experiments to knockdown GPR21 expression in HepG2 cells were 
performed using Selected Negative Control siRNA (Silencer Select Negative control 
siRNA, Ambion, Thermo Fisher Scientific Inc., Rockford, IL, USA) or GPR21 siRNA 
(GPR21 Silencer Select Pre-designed siRNA cod. s6037, Ambion, Thermo Fisher Scientific 
Inc., Rockford, IL, USA) according to the manufacturer’s protocol. 
HepG2 cells (1.2 × 106 cells) were seeded and immediately transfected with a Trans-
fection Reagent (Qiagen, Hilden, Germany) according to the manufacturer’s instructions 
up to 72 h. After 72 h, the HepG2 transfected cells were harvested for sample preparation. 
4.5. RNA Isolation and Quantitative Real-Time PCR (qPCR) 
GPR21 gene expression was quantified by a real-time qPCR. Total RNA was ex-
tracted by using TRI Reagent® (Sigma, Sigma-Aldrich, St Louis, MO, USA) according to 
the manufacturer’s instructions. Complementary DNA synthesis and quantitative real-
time PCR (q-PCR) reactions were performed on cell samples as previously described [57]. 
mRNA levels were measured by a q-PCR, using the SYBR® green method as described 
[58] The amplification mix was prepared using iTaq Universal Syber Green SuperMix (Bi-
orad Laboratories, Berkeley, CA, USA) following the manufacturer’s instructions and the 
real-time PCR was performed using Miniopticon ThermoCycler Instrument (Biorad La-
boratories, Berkeley, CA, USA). A real-time amplification of human GPR21 was carried 
out using the following set of primers: 
Human GPR21 FW 5′-TTTTCCACTGGGGCAAACCT-3′; 
Human GPR21 RV 5′-TTGGCAGATGCGGAAGATGT-3′. 
The housekeeping human gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was amplified in parallel, in all amplification sets, using the following set of 
primers: 
Human GAPDH FW 5′-TGGTATCGTGGAAGGACTCATGAC-3′; 
Human GAPDH RV 5′-ATGCCAGTGAGCTTCCCGTTCAGC-3′. 
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4.6. Western Blot Analyses 
About 30 µg of the total proteins were loaded for Western blot experiments, as pre-
viously described [53,59]. After blocking, the PVDF membranes were incubated at 4 °C 
overnight with antibodies against GPR21 (1 µg/uL, Abcam), p-Akt (1:1000, Cell Signaling 
Technology, #4051), Akt (1:1000, Cell Signaling Technology, #9272), p-Glycogen Synthase 
Kinase-3β (ph-GSK-3β, 1:1000, Cell Signaling Technology, #9322), GSK-3β (1:1000, Cell 
Signaling Technology, #9315), p-ERK (1:1000, Santa Cruz Biotechnology, sc-7383), ERK 
(1:1000, Santa Cruz Biotechnology, sc-94). To confirm equal protein loading, the mem-
branes were stripped and incubated with an anti-tubulin (1:5000, Abcam) monoclonal an-
tibody. Proteins of interest were detected with a horseradish peroxidase-conjugated sec-
ondary antibody (1:5000, Cell Signaling Technology) for 1 h at room temperature. The 
results were quantified using ImageJ software [60]. 
4.7. Glucose Uptake 
HepG2 cells (1 × 104 cells) were seeded in 96-well plates and after treatments, were 
incubated with 2-NBDG (Sigma, Sigma-Aldrich, St Louis, MO, USA) at a concentration of 
40 µM for 1 h at 37 °C. Then, the cells were washed three times with cold PBS and the 
fluorescence intensity was immediately measured on  the EnSight microplate reader 
(PerkinElmer, Waltham, MA, USA) at an excitation wavelength of 540 nm and an emission 
wavelength of 467 nm. An estimation of the overall glucose uptake was obtained by quan-
tifying the fluorescence. The 4′,6-diamidino-2-phenylindole (DAPI) nuclear dye was used 
for normalization. 
4.8. Glucose Production Assay 
HepG2 cells (1.2 × 106 cells) were seeded in 35 mm2 plates and after treatments they 
were washed three times to remove the remaining glucose. The medium was replaced 
with a glucose production buffer (glucose-free DMEM, without phenol red supplemented 
with 20 mM sodium lactate and 2 mM sodium pyruvate), as previously described [61]. 
After 3.5 h at 37 °C, the supernatants were collected to measure glucose concentration by 
the colorimetric assay Glucose Assay Kit MAK263 (Sigma, Sigma-Aldrich, St Louis, MO, 
USA) following the manufacturer’s instructions. 
4.9. Flow Cytometry Analysis 
HepG2 cells were seeded in 35 mm2 plates (1 × 106 cells/dish) and cultured in the 
following experimental conditions: (i) untreated cells; (ii) HepG2 cells treated with insulin 
100 nM for 1 h; (iii) HepG2 cells exposed to GRA2 30 µM for 24 h and (iv) HepG2 cells or 
transfected with non-silencing siRNA (SC) or with specific siRNA against GPR21 for 72 h. 
For each condition, the cells were rapidly washed with PBS, collected by trypsinization, 
and 5 × 105 cells were resuspended in a staining buffer (PBS plus 1–2% of FBS). To the 
cellular suspension, human serum (20%) was added for 30 min at 4 °C and then GLUT-2 
antibody (0.25 µg/106 cells) and Alexa Fluor 488 secondary antibody (1:500) for 30 min at 
4 °C. After incubation with antibodies, 2 mL of a staining buffer was added to wash the 
excess of antibodies and then the cells were centrifuged at 1900 rpm for 5 min. The super-
natants were discarded, and the cells were fixed with 400 µL of paraformaldehyde 1% 
(PAF) and analysed in flow cytometry. Detection of GLUT-2 green fluorescence (FL1) was 
performed on at least 5000 cells per sample with a FACScan equipped with a 488 nm argon 
laser using the CellQuest software (Becton-Dickinson, Milano, Italy). The peak of the FL1 
intensity of GLUT-2-stained control cells was set to channel 101 and retained for all meas-
urements. 
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4.10. Data Analysis 
Data are presented as mean ± SEM. Statistical significance was evaluated by the Stu-
dent’s t-test when applicable or a one-way analysis of variance (ANOVA) with a Bonfer-
roni post-hoc test. The analyses were performed by using the GraphPad Prism version 5.0 
for Windows (GraphPad Software, San Diego, California, USA), and p values < 0.05 were 
considered as significant. The significance was denoted as * p < 0.05, ** p < 0.01. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/ijms221910784/s1. 
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